{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T20:02:22Z","timestamp":1763755342545,"version":"3.45.0"},"reference-count":18,"publisher":"Oncology Nursing Society (ONS)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJON"],"published-print":{"date-parts":[[2016,10,1]]},"DOI":"10.1188\/16.cjon.466-469","type":"journal-article","created":{"date-parts":[[2016,9,26]],"date-time":"2016-09-26T13:29:34Z","timestamp":1474896574000},"page":"466-469","source":"Crossref","is-referenced-by-count":9,"title":["A Multidisciplinary Approach to Standardizing Processes for Blinatumomab Administration"],"prefix":"10.1188","volume":"20","author":[{"given":"Samantha","family":"DePadova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Howlett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2016,10,1]]},"reference":[{"key":"1","unstructured":"American Cancer Society. (2016). Cancer facts and figures 2016. Retrieved from www.cancer.org\/acs\/groups\/content\/@research\/documents\/document\/acspc -047079.pdf"},{"key":"2","unstructured":"Amgen, Inc. (2014). Blincyto\u00ae (blinatumomab) [package insert]. Retrieved from pi.amgen.com\/united_states\/blincyto\/blincyto_pi_hcp_english.pdf"},{"key":"3","unstructured":"Bassan, R., & Hoelzer, D. (2011). Modern therapy of acute lymphoblastic leukemia. Journal of Clinical Oncology, 29, 532\u2013543. doi:10.1200\/JCO.2010.30\u2028.1382"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Fielding, A.K., Richards, S.M., Chopra, R., Lazarus, H.M., Litzow, M.R., Buck, G., . . . Goldstone, A.H. (2007). Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study. Blood, 109, 944\u2013950.","DOI":"10.1182\/blood-2006-05-018192"},{"key":"5","doi-asserted-by":"crossref","unstructured":"G\u00f6kbuget, N., & Hoelzer, D. (2009). Treatment of adult acute lymphoblastic leukemia. Seminars in Hematology, 46, 64\u201375.","DOI":"10.1053\/j.seminhematol.2008.09.003"},{"key":"6","doi-asserted-by":"crossref","unstructured":"G\u00f6kbuget, N., Stanze, D., Beck, J., Diedrich, H., Horst, H., H\u00fcttmann, A., . . . Hoelzer, D. (2012). Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood, 120, 2032\u20132041.","DOI":"10.1182\/blood-2011-12-399287"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Hoffman, P., Hofmeister, R., Brischwein, K., Brandl, C., Crommer, S., Bargou, R., . . . Baeuerle, P.A. (2005). Serial killing of tumor cells by cytotoxic T cell redirected with a CD19-\/CD3-\u2028bispecific single-chain antibody construct. International Journal of Cancer, 115, 98\u2013104.","DOI":"10.1002\/ijc.20908"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Kantarjian, H., Thomas, D., O\u2019Brien, S., Cortes, J., Giles, F., Jeha, S., . . . Freireich, E.J. (2004). Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphoblastic leukemia. Cancer, 101, 2788\u20132801. doi:10.1002\/cncr.20668","DOI":"10.1002\/cncr.20668"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Kantarjian, H., Thomas, D., Wayne, A.S., & O\u2019Brien, S. (2012). Monoclonal antibody-based therapies: A new dawn in the treatment of acute lymphoblastic leukemia. Journal of Clinical Oncology, 30, 3876\u20133883. doi:10.1200\/JCO.2012.41.6768","DOI":"10.1200\/JCO.2012.41.6768"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Lee, D.W., Gardner, R., Porter, D.L., Louis, C.U., Ahmed, N., Jensen, M., . . . Mackall, C.L. (2014). Current concepts in the diagnosis and management of cytokine release syndrome. Blood, 124, 188\u2013195. doi:10.1182\/blood-2014-05-552729","DOI":"10.1182\/blood-2014-05-552729"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Le Jeune, C., & Thomas, X. (2014). Antibody-based therapies in B-cell lineage acute lymphoblastic leukemia. European Journal of Haematology, 94, 99\u2013108. doi:10.1111\/ejh.12408","DOI":"10.1111\/ejh.12408"},{"key":"12","unstructured":"National Cancer Institute. (2014). Common terminology criteria for adverse events (CTCAE). Retrieved from: http:\/\/ncit.nci.nih.gov\/ncitbrowser\/pages\/vocabulary.jsf?dictionary=CTCAE"},{"key":"13","unstructured":"National Cancer Institute. (2016). Surveillance, epidemiology, and end results program stat fact sheets: Acute lymphocytic leukemia. Retrieved from seer\u2028.cancer.gov\/statfacts\/html\/alyl.html"},{"key":"14","unstructured":"National Comprehensive Cancer Network. (2015). NCCN Clinical Practice Guidelines in Oncology: Acute lymphoblastic leukemia [v.2.2015]. Retrieved from www.nccn.org\/professionals\/physician _gls\/pdf\/all.pdf"},{"key":"15","doi-asserted-by":"crossref","unstructured":"O\u2019Brien, S., Thomas, D., Ravandi, F., Faderl, S., Cortes, J., Borthakur, G., . . . Kantarjian, H. (2008). Outcome of adults with acute lymphoblastic leukemia after second salvage therapy. Cancer, 113, 3186\u20133191. doi:10.1002\/cncr.23919","DOI":"10.1002\/cncr.23919"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Oriol, A., Vives, S., Hern\u00e1ndez-Rivas, J., Tormo, M., Heras, I., Rivas, C., . . . Ribera, J. (2010). Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHMA Study Group. Haematologica, 95, 589\u2013596. doi:10.3324\/haematol.2009.014274","DOI":"10.3324\/haematol.2009.014274"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Raponi, S., De Propris, M.S., Intoppa, S., Milani, M.L., Vitale, A., Elia, L., . . . Guarini, A. (2011). Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: Analysis of 552 cases. Leukemia and Lymphoma, 52, 1098\u20131107. \u2028doi:10.3109\/10428194.2011.559668","DOI":"10.3109\/10428194.2011.559668"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Topp, M.S., G\u00f6kbuget, N., Stein, A.S., Zugmaier, G., O\u2019Brien, S., Bargou, R.C., . . . Kantarjian, H.M. (2015). Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study. Lancet Oncology, 16, 57\u201366. doi:10.1016\/S1470-2045(14)71170-2","DOI":"10.1016\/S1470-2045(14)71170-2"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/cjon.ons.org\/cjon\/20\/5\/multidisciplinary-approach-standardizing-processes-blinatumomab-administration","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:52:27Z","timestamp":1763754747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/20\/5\/multidisciplinary-approach-standardizing-processes-blinatumomab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,1]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10,1]]}},"URL":"https:\/\/doi.org\/10.1188\/16.cjon.466-469","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2016,10,1]]}}}